As part of a Canadian Supercluster project, Canexia Health teams up with Novateur to investigate reimbursement strategy for cancer ‘liquid biopsy’
Canexia Health engaged Novateur’s expert team in 2020 to run a pan-Canadian reimbursement study as part of Project ACTT -- Access to Cancer Testing & Treatment in Response to COVID-19.
With a strategic investment from Canada’s Digital Technology Supercluster, Project ACTT is speeding up cancer testing for targeted treatment selection during and beyond the pandemic through a minimally invasive ‘liquid biopsy’ test that analyzes circulating tumor DNA (ctDNA).
ctDNA testing, which requires only a simple blood draw from the patient, can be an effective alternative to some surgical tissue biopsies to guide cancer targeted treatment and can improve patient outcomes two- to three-fold. Yet, this testing is not accessible to most Canadian cancer patients.
Ultimately, Canexia is working with Novateur to demonstrate that ctDNA testing should be delivered under provincial health coverage -- making it accessible to Canadian cancer patients regardless of where they live.
Learn more about Canexia Health